Illumina, Inc. Q1 2024 Form 10-Q Summary
Business context and reporting period
Illumina provides sequencing- and array-based genomic solutions for research, clinical, and applied markets. The filing covers the 13-week quarter ended March 31, 2024, compared with the 13-week quarter ended April 2, 2023. Reportable segments are Core Illumina and GRAIL, which is being held and operated separately pending divestiture.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Total revenue | $1,076 million | $1,087 million | Down 1% |
| Product revenue | $876 million | $922 million | Down 5% |
| Service and other revenue | $200 million | $165 million | Up 21% |
| Gross profit | $667 million | $655 million | Up 2% |
| Gross margin | 62.0% | 60.3% | Up 170 basis points |
| Loss from operations | $(111) million | $(64) million | Worsened $47 million |
| Net loss | $(126) million | $3 million net income | Worsened $129 million |
| Diluted loss per share | $(0.79) | $0.02 | Declined |
| Operating cash flow | $77 million | $10 million | Improved $67 million |
Core Illumina revenue was $1,056 million, down 2%, primarily due to a $46 million decrease in instrument revenue. Core Illumina operating income was $116 million versus $142 million in the prior-year quarter. GRAIL revenue increased to $27 million from $20 million, while its operating loss widened to $227 million from $204 million.
Operating expenses increased 8% to $778 million. Research and development expense declined modestly to $339 million, while selling, general and administrative expense increased 16% to $439 million. The increase included $36 million of restructuring charges, a $17 million loss from remeasuring GRAIL-related contingent consideration, and $7 million of accrued interest on the European Commission fine.
Cash and cash equivalents were $1,108 million at March 31, 2024, compared with $1,048 million at December 31, 2023. Including $7 million of short-term investments, total cash, cash equivalents, and short-term investments were $1,115 million. Approximately $614 million of cash and cash equivalents was held by foreign subsidiaries.
Investing cash outflows were $48 million, including $36 million of capital expenditures and $12 million of strategic investments. Financing cash inflows were $35 million, primarily from employee stock issuance. The company had $1,490 million of net term notes outstanding and no borrowings or letters of credit under its $750 million revolving credit facility. Term notes mature in 2025, 2027, and 2031.
Material changes versus the prior comparable period
- Revenue declined slightly because of lower sequencing instrument shipments, including fewer high-throughput and mid-throughput instruments. Customer capital and cash-flow constraints continued to affect purchasing behavior.
- Consumables revenue was broadly stable overall, with higher sequencing consumables revenue offsetting lower microarray consumables revenue.
- Service and other revenue increased, driven primarily by strategic partnerships and higher GRAIL Galleri-related revenue.
- Gross margin improved due to a more favorable sequencing-consumables mix, freight savings, and productivity improvements, partly offset by lower-margin strategic partnership revenue and higher warranty and field-service costs.
- Operating performance deteriorated despite higher gross profit because of increased SG&A, restructuring charges, GRAIL-related items, and accrued interest on the European Commission fine.
- The company reported a $17 million income tax provision in Q1 2024, compared with an $81 million tax benefit in Q1 2023. The Q1 2024 effective tax rate was negative 15.3%, versus positive 103.9% in Q1 2023; the company changed to a year-to-date effective tax rate method for Q1 2024.
Outlook, commentary, risks, and unusual items
Management expects inflation, foreign-exchange fluctuations, uncertain economic growth, competitive conditions in China, Russia-related sanctions, and customer inventory and capital discipline to continue affecting 2024 results. The filing does not provide a specific full-year revenue or earnings guidance figure.
Illumina expects current cash, operating cash flow, and available revolver capacity to fund near-term operating and capital needs for at least the next 12 months. The company does not intend to repurchase shares during fiscal 2024; no shares were repurchased in Q1 2024.
Illumina announced its intention to divest GRAIL and received European Commission approval of its divestment plan on April 12, 2024. Management targeted finalizing divestiture terms by the end of Q2 2024, but stated that timing is uncertain. The divestiture is expected to require funding sufficient for at least 2.5 years of GRAIL operations, estimated at approximately $1 billion including GRAIL cash.
The European Commission imposed a fine of approximately €432 million related to the GRAIL acquisition. Illumina accrued $478 million, including interest and foreign-exchange effects, as of March 31, 2024; the fine accrues interest at 5.5% annually while outstanding. The company provided guarantees rather than paying the fine while pursuing appeals.
Material legal and regulatory matters include the GRAIL divestiture and related appeals, an SEC investigation, a Department of Justice civil investigative demand concerning alleged cybersecurity-related False Claims Act issues, securities class actions, shareholder derivative litigation, and a books-and-records action. Outcomes and potential additional losses cannot be predicted from the filing.
Q1 2024 included $36 million of restructuring charges, primarily facility-related impairments, including $32 million of asset impairment charges. The company had approximately $142 million of remaining assets related primarily to affected Foster City and San Diego facilities. GRAIL-related contingent consideration was valued at $403 million at quarter-end, and unvested GRAIL cash-based equity awards had an aggregate value of $279 million.
Important facts for investors to verify
- Progress, timing, funding requirements, tax consequences, and ultimate terms of the GRAIL divestiture.
- Status and potential financial impact of the European Commission fine, related appeals, and any additional regulatory remedies or penalties.
- Whether lower instrument demand and customer capital constraints persist, particularly in China and other pressured markets.
- Core Illumina operating leverage and whether cost reductions can offset restructuring, legal, GRAIL-related, and facility costs.
- Potential exposure from the SEC investigation, DOJ demand, securities actions, derivative suits, and other GRAIL-related litigation.
- Ability to maintain liquidity while funding GRAIL operations, repaying or refinancing the 2025 term notes, and meeting capital and operating requirements.